Leighl NB, Hellmann MD, Hui R, et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. J Clin Oncol. 35, 2017 (suppl; abstr 9011).
Adjuvant ipilimumab bij stadium III-melanoom
jan 2017 | Dermato-oncologie, Immuuntherapie